摘要
目的 :了解利培酮对老年期精神分裂症的疗效与安全性。方法 :对 35例年龄≥ 6 0岁的精神分裂症患者进行为期 8周的观察 ,以 PANSS评定疗效 ,以 TESS评定不良反应 ,在治疗前及治疗后 1、2、4和 8周末评定各量表。结果 :利培酮治疗剂量为 (2 .32± 1.4 7) mg/ d,总有效率 77.14 % ,显效率 4 0 % ,PANSS总分及各因子分值于治疗前后均有显著性差异 (P <0 .0 5 ,P <0 .0 1) ,起效时间为 2周 ,不良反应轻 ,病人能耐受 ,并不影响治疗。结论 :利培酮对老年期精神分裂症的阳性和阴性症状均有效 ,且起效较快 ,治疗剂量低 ,依从性好 ,安全性高 ,可作为老年期精神分裂症的首选用药之一。
Objective: To explore the efficacy and safety of risperidone in treating senile patients with schizophrenia. Method: 35 patients with schizophrenia over 60 year old were observed for 8 weeks. Results: The effective dose of risperidone was in the range of(2.32±1.47) mg/d. The effective rate was 77.14%, the marked improved rate was 40%, Both total score, and factor scores of PANSS before treatment and those after treatment are significantly different(P<0.05, P<0.01). The therapeutic effect occured after 2 weeks, the side effect was mild, and patients had good compliance, Conclusion: Risperidone has significant therapeutic effect in treating senile patients with schizophrenia. Both positive and negative symptoms can be improved with low dose rispcridone and good compliance. Risperidone may be the first class drug in the treatment of senile schizophrenia.
出处
《天津药学》
2002年第3期56-57,共2页
Tianjin Pharmacy
